miromatrix medical inc. is a life science company that has a novel and proprietary technology to remove cells from, or decellularize, organs and tissues from animal and human sources, facilitating the creation of numerous products, including the potential of fully biological transplantable human organs.
Company profile
Ticker
MIRO
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
271285782
MIRO stock data
Latest filings (excl ownership)
15-12G
Securities registration termination
26 Dec 23
8-K
Completion of Acquisition or Disposition of Assets
18 Dec 23
EFFECT
Notice of effectiveness
18 Dec 23
POS AM
Prospectus update (post-effective amendment)
13 Dec 23
S-8 POS
Registration of securities for employees (post-effective amendment)
13 Dec 23
S-8 POS
Registration of securities for employees (post-effective amendment)
13 Dec 23
SC 14D9/A
Tender offer solicitation (amended)
13 Dec 23
SC TO-T/A
Third party tender offer statement (amended)
13 Dec 23
25-NSE
Exchange delisting
13 Dec 23
SC 14D9/A
Tender offer solicitation (amended)
12 Dec 23
Transcripts
MIRO
Earnings call transcript
2023 Q2
14 Aug 23
MIRO
Earnings call transcript
2023 Q1
11 May 23
MIRO
Earnings call transcript
2022 Q4
31 Mar 23
MIRO
Earnings call transcript
2022 Q3
15 Nov 22
MIRO
Earnings call transcript
2022 Q2
16 Aug 22
MIRO
Earnings call transcript
2022 Q1
17 May 22
MIRO
Earnings call transcript
2022 Q4
31 Mar 22
MIRO
Earnings call transcript
2022 Q3
15 Nov 21
Latest ownership filings
SC 13G/A
DAVITA INC.
14 Feb 24
SC 13G/A
LYTTON LAURENCE W
14 Feb 24
SC 13D
UNITED THERAPEUTICS Corp
22 Dec 23
3
Initial statement of insider ownership
14 Dec 23
4
Lisa Wipperman Heine
13 Dec 23
4
Peter Maag
13 Dec 23
4
JOHN L ERB
13 Dec 23
4
PAUL BUCKMAN
13 Dec 23
4
William P. Mr. Burke
13 Dec 23
4
James Michael Douglas
13 Dec 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 6.92 mm | 6.92 mm | 6.92 mm | 6.92 mm | 6.92 mm | 6.92 mm |
Cash burn (monthly) | (no burn) | (no burn) | 2.21 mm | 2.38 mm | 1.52 mm | 2.03 mm |
Cash used (since last report) | n/a | n/a | 15.16 mm | 16.33 mm | 10.44 mm | 13.88 mm |
Cash remaining | n/a | n/a | -8.24 mm | -9.42 mm | -3.53 mm | -6.97 mm |
Runway (months of cash) | n/a | n/a | -3.7 | -4.0 | -2.3 | -3.4 |
Institutional ownership, Q3 2023
35.1% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 34 |
Opened positions | 2 |
Closed positions | 2 |
Increased positions | 9 |
Reduced positions | 6 |
13F shares | Current |
---|---|
Total value | 8.57 bn |
Total shares | 9.63 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
First Light Asset Management | 2.28 mm | $2.99 bn |
DVA DaVita | 1.98 mm | $9.29 mm |
Gagnon Securities | 1.46 mm | $1.91 bn |
Gagnon Neil | 922.89 k | $0.00 |
Vanguard | 658.55 k | $862.70 mm |
Gagnon Advisors | 556.76 k | $729.35 mm |
RTW Investments | 445.22 k | $583.24 mm |
Mayo Clinic | 191.62 k | $251.03 mm |
Geode Capital Management | 173.78 k | $210.34 mm |
G2 Investment Partners Management | 168.72 k | $221.03 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
13 Dec 23 | Jeffrey James Ross | Common Stock | Sale back to company | Dispose D | No | No | 0 | 87,500 | 0.00 | 0 |
13 Dec 23 | Jeffrey James Ross | Employee Stock Option Common Stock | Sale back to company | Dispose D | No | No | 3.26 | 100,000 | 326.00 k | 0 |
13 Dec 23 | Jeffrey James Ross | Employee Stock Option Common Stock | Sale back to company | Dispose D | No | No | 4.2 | 100,000 | 420.00 k | 0 |
13 Dec 23 | Jeffrey James Ross | Employee Stock Option Common Stock | Sale back to company | Dispose D | No | No | 4.73 | 1,500 | 7.10 k | 0 |
13 Dec 23 | Jeffrey James Ross | Employee Stock Option Common Stock | Sale back to company | Dispose D | No | No | 3.75 | 68,714 | 257.68 k | 0 |
13 Dec 23 | Jeffrey James Ross | Employee Stock Option Common Stock | Sale back to company | Dispose D | No | No | 3.75 | 100,000 | 375.00 k | 0 |
13 Dec 23 | Jeffrey James Ross | Employee Stock Option Common Stock | Sale back to company | Dispose D | No | No | 3.75 | 39,375 | 147.66 k | 0 |
13 Dec 23 | Jeffrey James Ross | Employee Stock Option Common Stock | Sale back to company | Dispose D | No | No | 3.75 | 33,688 | 126.33 k | 0 |
13 Dec 23 | Jeffrey James Ross | Employee Stock Option Common Stock | Sale back to company | Dispose D | No | No | 3.75 | 43,750 | 164.06 k | 0 |
13 Dec 23 | Jeffrey James Ross | Employee Stock Option Common Stock | Sale back to company | Dispose D | No | No | 3.75 | 41,250 | 154.69 k | 0 |